Immunomedics (IMMU) – Globe Newswire
-
Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting
-
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors
-
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
-
Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma
-
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
-
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
-
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
-
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
-
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
-
Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers
-
Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020
-
Immunomedics Announces Key Oral Presentations at ESMO Virtual Congress 2020
-
Immunomedics to Participate in Upcoming Healthcare Conferences
-
Immunomedics to Participate in Upcoming Healthcare Conferences
-
Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™
-
Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™
-
Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update
-
Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update
-
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020
-
Immunomedics to Report Second Quarter 2020 Results and Host Conference Call and Webcast on August 5, 2020
-
Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers
-
Immunomedics Expands Collaboration with Roche Evaluating Trodelvy™ (sacituzumab govitecan-hziy) in Combination with Tecentriq® (atezolizumab) into Urothelial and Non-Small Cell Lung Cancers
-
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
-
Immunomedics Announces Positive Results from Phase 3 ASCENT Study of TRODELVY™ in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer (mTNBC)
-
Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update
-
Immunomedics to Host Conference Call and Webcast on July 6, 2020 to Provide Clinical Update
-
Immunomedics to Participate in Upcoming Healthcare Conferences
-
Immunomedics to Participate in Upcoming Healthcare Conferences
-
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
-
Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19
-
Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting
-
Immunomedics to Present New Trodelvy™ Data In Non-Breast Cancer Indications at the 2020 ASCO Virtual Meeting
-
Immunomedics to Participate in BofA Securities 2020 Health Care Conference
-
Immunomedics to Participate in BofA Securities 2020 Health Care Conference
-
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update
-
Immunomedics Reports First Quarter 2020 Results and Provides Corporate Update
-
Immunomedics Announces Commercial Availability of TRODELVY™ in the United States
-
Immunomedics Announces Commercial Availability of TRODELVY™ in the United States
-
Immunomedics Announces Closing Of Public Offering Of Common Stock
-
Immunomedics Announces Closing Of Public Offering Of Common Stock
-
Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020
-
Immunomedics to Report First Quarter 2020 Results and Host Conference Call and Webcast On May 6, 2020
-
Immunomedics Announces Pricing of Public Offering of Common Stock
-
Immunomedics Announces Pricing of Public Offering of Common Stock
-
Immunomedics Announces Proposed Public Offering Of Common Stock
-
Immunomedics Announces Proposed Public Offering Of Common Stock
-
CORRECTION: Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Nega
-
Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast
-
Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
-
Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer
Back to IMMU Stock Lookup
